1. Adipose tissue mass is dependent on both the average volume and the number of its constituent adipocytes. Significant alteration in body mass involves alteration in both adipocyte volume and number.
2.
Increases in adipocyte number occur via replication and differentiation of preadipocytes, a process which occurs throughout life. Decreases in adipocyte number occur via preadipocyte and adipocyte apoptosis, and possibly adipocyte dedifferentiation. 3. Overall regulation of adipose mass involves endocrine, paracrine and possibly autocrine systems. Hypothalamic centres appear to control appetite, metabolic rate and activity levels in a co-ordinated manner. Within the hypothalamus, known weight regulatory molecules include glucagon-like peptide-1, neuropeptide Y and leptin.
Leptin is a major afferent signal from adipose tissue to the hypothalamus, providing information on overall adipose tissue mass. However, the precise means by which the hypothalamus signals to adipose tissue is less well understood. 4. In adipose tissue, known molecular regulators of adipose cell number include insulin, ligands for the peroxisome proliferator activated receptor-y, retinoids, corticosteroids and tumour necrosis factor-a. The net effect of these and other regulators is to effect a concerted alteration in adipocyte volume and number. This review largely focuses on the control of fat cell acquisition and loss and the influence of these processes on adipose tissue mass and regional distribution. is considerable evidence that the incidence of both disorders is increasing, and therefore it is obvious that effective treatments or interventions for both disorders would alleviate much suffering, and may also reduce healthcare costs significantly. It is for this reason that adipose tissue research has undergone a resurgence in recent years -a resurgence buoyed by some major advances in our understanding of the pathophysiology of this complex tissue. It is now recognized to be a biologically active and dynamic tissue, with major endocrine and possibly immunological roles as well as its 'traditional' function as an energy storage depot.
Adipose tissue has a characteristic and unique feature in its enormous potential for volume (and hence mass) change. For example, the major tissue alteration that occurs in an individual whose weight increases from 70 to 150 kg is the quadrupling of fat mass -the skeletal and muscle mass remaining relatively (compared with the change in fat mass) unchanged. Should this individual then, by reducing energy intake but maintaining nutrition, slowly return to his 'ideal' weight, the reverse would occur with marked loss of adipose tissue and relative sparing of skeletal and muscle mass. How can adipose tissue accommodate these changes, what are their short-and long-term effects, and how are these processes regulated?' Recent progress in our understanding of factors regulating adipose mass has provided some insight into these questions, and the aim of this review is to examine the contribution of changes in adipose cell number to the regulation of adipose tissue mass. of food eaten). Depending on activity levels, 55-75% of human energy requirements are related to BMR [l] . That energy expenditure is amenable to change (aside from the effects of exercise) is evidenced by, for example, studies of individuals with thyroid disease, inflammatory diseases or pyrexia. However, even in view of the plasticity of BMR and (often dramatic) alterations in energy intake and exercise-related expenditure, most adults remain relatively constant in weight throughout their lives. This weight constancy suggests the possibility that BMR, appetite and energy expenditure are in some way linked, a notion supported in recent years by the realization that hypothalamic regions appear to control all three factors.
Evidence that body weight (and hence possibly BMR, appetite and levels of energy expenditure) may be genetically controlled comes from epidemiological, twin and adoption studies. These indicate that adult weight and fat distribution are genetically determined to a significant extent with a smaller environmental influence over adult weight or body mass index 121 and up to 85% of population variance in central abdominal fat attributable to genetic influences [3] .
A question that has challenged researchers for decades pertains to the means whereby the hypothalamic centres controlling BMR, appetite and energy expenditure (and hence adipose mass) 'know' how fat the individual is at any time. The now classical parabiosis experiments of the 1960s (reviewed in [4] ) suggested the existence of an endocrine feedback loop, and the recent identification of leptin [5] and its receptors [6, 71 have given dramatic support to this concept and led to improved understanding of the system. Further studies of the leptin hormonal axis indicate that it may be a significant regulator of BMR and that it appears to regulate appetite and activity levels and to influence the gonadal, thyroid and adrenal axes [12, 131 . Furthermore, the immense power of the leptin system is demonstrated by the parabiosis experiments in which animals exposed to (what we now realize to be) high and unregulated levels of leptin starved to death.
Given that the total mass of adipose tissue appears to be centrally controlled [14] to a large degree, a key question is how the message to increase or decrease adipose mass is signalled.
MECHANISMS OF REGULATION OF ADIPOSE MASS 'Central' regulation of adipose mass
The leptin system is receiving enormous research attention currently, but the actual central signalling pathways involved in transducing the leptin signal await delineation. It is clear that other signalling molecules are involved, not least glucagon-like peptide-l,5-hydroxytryptamine and neuropeptide Y, and an increased understanding of the interrelationships between these and other neurotransmitters may provide avenues for intervention. That this approach is at least feasible is shown by the efficacy of leptin administration (to rodents) in the induction of weight loss, and the effect of centrally acting drugs (e.g. dexfenfluramine, barbiturates) to assist in weight loss. Because BMR, appetite and activity levels appear to be centrally controlled, manipulation of the 'central' weight regulatory system offers an attractive avenue for pharmacological intervention.
Relationships between higher centres and adipose tissue
While hunger and satiety can be seen to induce weight gain or loss by a direct alteration in energy balance, the way in which a central (presumed hypothalamic) 'decision' to alter metabolic rate is mediated is not well understood (Fig. 1) 
Local regulatory mechanisms in adipose tissue
Adipocyte size and number appear to be regulated in a co-ordinated manner. In weight gain, adipocyte volume and number increase. Similarly, when adipose loss occurs, adipocyte volume and number appear to reduce in concert. This suggests that local (paracrine) systems may be in part responsible for the regulation of adipose mass. The signalling pathways involved are as yet unknown, and an understanding of them, and possibly depot-related differences in them, may lead to interventions which could modify adipose mass via a local effect.
ADIPOSE TISSUE MASS REFLECTS ADIPOCYTE SIZE AND NUMBER
At any point in time, adipose tissue mass reflects the number and average volume of the component adipose cells [17] . Cell number and volume in turn reflect the balance of processes that decrease or increase each parameter (Fig. 2) . Thus, because lipogenesis and lipolysis occur continuously in all adipocytes, with cytoplasmic lipid being in a state of Lipogenesis and lipolysis are well-characterized processes affecting adipose cells, and can be relatively easily assessed in vitro. There is a substantial literature on these processes, and their controls and regulation in vivo and in vitro [18, 191. In general terms, insulin and acylation stimulating protein [20] are the major lipogenic influences and catecholamines, thyroid hormones and growth hormone the major lipolytic influences. However, changes in cell volume are insufficient to fully account for variations in adipose mass either within or between individuals [17, 211. Indeed, adipocyte volume and number appear to be in some way m ADIPOCYTE ( ADIPOCYTE 1 NUMBER u co-regulated. This is clemonstrated by studies demonstrating that in a sckting of weight gain, there is an initial increase in adipocyte volume until a 'critical' point is reached, and thereafter recruitment of new cells occurs [22] . This review will concentrate on the regulation of .Idipose cell number, and the mechanisms by which it may be increased or decreased.
EVIDENCE THAT ADIPOSE CELL NUMBER IS VARIABLE
While many studi,:s have compared adipocyte volume and number between individuals, few studies have examined these parameters prospectively in the . Hence, the only explanation is that obese individuals have a greater number of fat cells, and this was confirmed by Hirsch in 1971 [17] . Given that all obese individuals had at some stage less adipose tissue, these observations suggest that fat cell acquisition can occur in adult life. The identification of adipocyte stem cells (preadipocytes) [24] and the recognition of the adipocyte replication/differentiation program [25, 261 provided a mechanism by which adipose cells could be acquired at any stage of life (Fig. 3) . The ability to repeat this replication/differentiation program in vitro, and the demonstration that preadipocytes injected subcutaneously in nude mice develop into mature fat pads [27], has provided convincing and well-accepted evidence that adipose cell acquisition occurs by this mechanism in vivo.
However, while the notion of adipocyte acquisition has gained widespread acceptance, it has also been generally accepted that this acquisition is permanent [28] . This is despite the knowledge that the vast majority of mammalian tissues are dynamic, and, as outlined above, the observation that in most individuals fat mass is relatively stable over time. This suggests that if adipose cell acquisition does occur in vivo, then a process of cell deletion must also be occurring to maintain cell number. Furthermore, based on our understanding of other tissues, this process is likely to be apoptosis.
Evidence for adipose cell loss does indeed exist. Firstly, a study by Geloen et 
Thus it is clear that adipose cell acquisition may occur via the process of preadipocyte replication/ differentiation, and it is likely that it may do so at any stage of life.
Adipose cell loss
Two distinct mechanisms of adipocyte loss have been described -dedifferentiation and apoptosis.
Adipocyte dedifferentiation [45, 481 is the in vitro process in which terminally differentiated cells revert morphologically and biochemically to less differentiated cell types -in this case preadipocytes.
The process was first described by Van We have previously demonstrated that human adipocyte apoptosis may be induced in vitro [52] , and that it occurs in vivo, at least in a proportion of patients with malignancy [32] . These studies indicate that human adipocytes are able to undergo apoptosis, and therefore suggest the likelihood that the adipose cell mass is dynamic. This proposal is further strengthened by our observations (J. B. Prins, N. I. Walker, C. Winterford and D. P.
Cameron, unpublished work) that human preadipocytes may also be induced to undergo apoptosis in vitro, indicating that stem cell commitment to the adipocyte lineage is not irreversible.
Thus, study of adipose mass from the perspective of cell number must include, at the very least, the study of factors influencing preadipocyte replication, preadipocyte differentiation, preadipocyte/adipocyte apoptosis, and possibly adipocyte dedifferentiation. At present, experimental models of preadipocyte differentiation are "well established and much utilized, and consequently there is a considerable literature available (albeit relatively little regarding human cells). In contrast, adipose cell apoptosis in particular is understudied.
KNOWN AND POTENTIAL MOLECULAR REGULATORS OF ADIPOCYTE NUMBER

Insulin
Insulin is the classical anabolic hormone [53] , and as such might be expected to stimulate the acquisition of fat cells. In support of this concept is the weight (including adipose tissue) loss associated with insulinopaenia that occurs in disease -insulindependent diabetes mellitus -or experimental situations -e.g. streptozotocin-treated rodents. In both situations, restoration of circulating insulin levels restores fat mass [54] . Histological studies in experimental insulinopaenia demonstrate that there is loss of adipose cells, not just of cytoplasmic lipid [29] . This loss of cells is likely to occur by apoptosis, a postulate consistent with the known anti-apoptotic role of insulin in other settings. Furthermore, insulin excess appears to promote adipose tissue gain. This appears to occur disproportionately in the visceral depot and is seen in patients with the syndrome of hyperinsulinaemia, hypertension and hyperlipidaemia (Syndrome X) [55] , patients with insulinoma [56] , and patients with non-insulin-dependent diabetes treated with high-dose insulin. That the adipose deposition is visceral in all these groups indicates that the distribution pattern cannot be explained by portal-systemic differences in insulin concentrations, and therefore is likely to reflect siterelated differences in the (pre)adipocyte response to insulin.
Insulin In vitro studies support the adipogenic effect of insulin. Cultured preadipocyte replication and differentiation are stimulated by insulin [42] , and indeed, insulin is an obligate hormone for human preadipocyte differentiation [63] .
Thus, insulin is able to exert an adipogenic influence by a number of mechanisms: stimulation of preadipocyte replication, stimulation of preadipocyte differentiation, and possibly suppression of adipo-cyte apoptosis. Furthermore, it may also have a central anti-adipogenic effect through regulation of leptin and neuropeptide Y.
PPAR-y and its ligands
PPAR-y is a member of the nuclear receptor superfamily [64-661, and is highly expressed in adipose tissue. Recent evidence suggests that the natural ligand for the receptor is an arachidonic acid metabolite, prostaglandin 52 [67, 681 . Of equal interest is the fact that members of a new class of insulin-sensitizing drugs -thiazolidinediones -are also ligands for PPAR-y [69] . It appears that the PPAR-y (and presumably available ligand) is necessary for preadipocyte differentiation to occur. Indeed, expression of the receptor into non-preadipocyte cells commits them to the adipocyte lineage [44] , suggesting that PPAR-y expression is of crucial importance in the preadipocyte-adipocyte differentiation pathway [43, 701 . In vitro studies have demonstrated that exposure of murine preadipocytes to ligands for PPAR-y -either prostaglandin J2 or thiazolidinediones -dramatically enhances the differentiation process [71] . This would indicate a possible in vivo mechanism by which preadipocyte acquisition (and hence adipocyte number) could be controlled. That the natural ligand appears to be a prostaglandin raises the possibility that dietary alterations may -by modifying prostaglandin concentration and type -affect adipose cell number by a relatively direct means. The relationship between the adipogenic and insulin-sensitizing effects of thiazolidinediones is as yet unknown, but is under active investigation. These studies should provide further insights into the complex interplay between adipose tissue and insulin sensitivity.
Retinoids
Retinoids are natural and synthetic analogues of vitamin A (retinol). The compounds have complex effects on the replication, differentiation and apoptosis of numerous cell types including preadipocyte cell lines. In high concentration retinoids enhance replication of preadipocytes in vitro [72] . Retinoids also have effects on preadipocyte differentiation -stimulatory in low concentration [73] and inhibitory in high concentration [72] . The mechanism of action of retinoids in modulating preadipocyte differentiation appears to be via retinoic acid receptors (RXR and RAR), and it is likely that the PPAR-y receptor may be a co-regulator [70, 741 . The effect of retinoids on adipose cell apoptosis is unknown.
These findings again raise the possibility that dietary content may have direct effects on regulation of adipose cell number and hence adipose tissue mass.
Corticosteroids
Although the effect of corticosteroids on protein is clearly catabolic, the effect on adipose tissue is not as well defined but tends to be anabolic. This is best characterized in patients with supraphysiological levels of corticosteroids, either endogenous (Cushing's syndrome) or exogenous (iatrogenic through steroid therapy). These individuals have overall weight gain despite muscle loss. Although a proportion of the gained weight is due to fluid retention, there is also adipose tissue gain. Again, this predominantly affects the visceral depot and there may at times be loss of subcutaneous adiposity. These changes are often obvious clinically (and indeed represent some of the classical clinical features of Cushing's) and are also demonstrable radiologically [75] . The opposite clinical scenario is present in Addison's disease (corticosteroid deficiency) in which adipose tissue loss is a feature, as is the case after reduction of supraphysiological corticosteroid levels. Furthermore, epidemiological studies suggest a positive correlation between physiological range corticosteroid levels and (particularly visceral) obesity [76-781. These studies suggest that corticosteroids may have a fundamental role in regulation of energy and hence adipose balance. This role is complex, with effects at the level of adipose tissue such as regulation of lipoprotein lipase activity [79] and induction of insulin resistance [SO] and GLUT4 gene expression [MI, as well as central effects via ob [82] and glucagon-like peptide-1 [83] .
Again, in vitro studies tend to support the adipogenic effect of corticosteroids with the demonstration that the hormones promote human preadipocyte differentiation [41] . In contrast to the effect of insulin however, preadipocyte replication is not enhanced by corticosteroids. The effect of the hormones on adipocyte apoptosis is not known.
TNF-a
There is increasing evidence that TNF-a has a major metabolic role in adipose tissue [84] . TNF is produced by human preadipocytes and adipocytes and this production is higher in obesity, with up to 3-fold increases in TNF-a mRNA, protein [85] and circulating levels [86] . There is evidence that this role may include the regulation of adipocyte function and possibly number.
With respect to adipocyte function, TNF-a induces insulin resistance by at least two mechanisms -downregulation of insulin receptor tyrosine kinase activity [87] and through induction of an abnormality in insulin receptor substrate-1 which inhibits phosphorylation of components of the insulin signalling cascade [88] . The net effect of the induction of insulin resistance in adipocytes is likely to be lipolysis, given that insulin has a primarily anti-lipolytic function in these cells. Furthermore, TNF-a induces lipolysis in adipocytes by direct effects on lipoprotein lipase activity (downregulation) and hormone-sensitive lipase activity (upregulation) [89] . Thus, adipose mass is likely to decrease, or at least be less likely to increase, depending on nutrient balance. Whether the 'insulin resistance' induced by TNF-a is purely to insulin's metabolic effects is unknown, as the effect of TNF-a on the mitogenic and anti-apoptotic effects on insulin has not been studied.
With respect to cell number, TNF-a also has multiple actions. It suppresses human preadipocyte differentiation, and causes delipidation and dedifferentiation of adipocytes [51] , effects that are blocked by thiazolidinediones [90] . We have also shown that it induces human adipocyte and preadipocyte apoptosis in vitro (J. Thus the net effect of TNF-a on adipose tissue is one of reduction of adipose mass, through reduction in both cell number and volume. It is for these reasons that TNF-a has been proposed to be the 'link' between insulin resistance (and Type I1 diabetes) and obesity. It also raises the possibility that the increase in adipocyte TNF-a production in obesity may be a protective mechanism, in some way limiting the potential of the individual to gain weight. This concept has the attraction of ensuring that adipose accumulation to a degree that would impair mobility would not occur. However, like many physiological 'protective' mechanisms it also has disadvantages -in the setting of long-term overnutrition, fat mass may be preserved at the expense of hyperlipidaemia with consequent exacerbation of cardiac (and other) risk.
Central regulatory molecules -leptin, glucagon-like peptide-I, neuropeptide Y, 5-hydroxytryptamine
Leptin is a peptide hormone produced by adipocytes, and it appears to act primarily on hypothalamic receptors. It has the effect of reducing food intake and increasing metabolic rate, and causes significant adipose tissue loss when administered parenterally to oblob mice (which lack intact leptin) and normal rodents. The hypothalamic signalling pathway of the leptin system has not yet been characterized, but it appears that neuropeptide Y is involved [14, Elucidation of the mechanism by which the central signal originating from these molecules (alone or in combination) is translated to mediate change in adipose cell number or volume will provide an important advance in our understanding of adipose tissue regulation, and uncover a further potential site for intervention.
ROLE OF DIFFERENTIAL REGULATION OF ADIPOSE CELL NUMBER IN DETERMINATION OF ADIPOSE TISSUE DISTRIBUTION
Excess intra-abdominal adiposity is more strongly associated with morbidity and mortality from cardiovascular disease and non-insulin-dependent diabetes than is the degree of obesity per se. Factors regulating adipose tissue distribution are largely unknown but in addition to genetic influences, there is evidence for roles of steroid hormones, insulin, growth hormone, catecholamines, exercise and environmental factors. In general terms, patterns of adipose tissue distribution may be the result of depot-specific intrinsic differences in adipose cells, depot-specific differences in factors influencing adipose cell number and/or volume, or unequal contributions to the adipose-hypothalamic 'feedback loop' from different adipose tissue depots.
Evidence exists supporting all three possibilitiesin each case providing a possible means by which adipose cell number could be differentially regulated in clinically important depots. Firstly, glucocorticoid receptor number is greater in omental than subcutaneous adipocytes [loo] . This allows differential corticosteroid-induced regulation of adipose cell volume and number. Secondly, the higher insulin concentration in the portal vasculature may contribute to differential effects of insulin on adipose tissue mass in visceral and subcutaneous depots. Thirdly, we have recently demonstrated that subcutaneous and omental adipocytes express different amounts of leptin mRNA [loll. Hence the two adipose depots could differentially contribute to circulating leptin levels and hence to central regulation of overall adiposity. A greater understanding of regional regulation of adipose cell number may lead to interventions aimed at modifying adipose distribution rather than overall adiposity -an intervention likely to promote substantial reduction in morbidity and mortality.
CONCLUSION
In this review we have attempted to outline the current understanding of factors regulating adipose mass, with particular emphasis on the regulation of adipose cell number. We have also indicated a number of areas in which further research may lead to the development of fundamentally different intervention strategies aimed at modifying adipose mass or distribution.
While the simplest, best and most elegant treatment for disorders of adipose mass is still the modification of diet and exercise patterns, this intervention is either impossible, impractical or not achievable for a great many individuals. It is hoped that recent major advances in our understanding of adipose tissue regulation will be expanded upon, and that the current resurgence in research interest will lead to the development of alternative and effective interventions.
